

SKYEPHARMA PLC
Form 6-K
January 20, 2006

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of January , 2006

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

For Immediate Release

Edgar Filing: SKYEPHARMA PLC - Form 6-K

SkyePharma Responds to Call for EGM

LONDON, UK, 20 January 2006 -- SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) notes with disappointment North Atlantic Value LLP and two other institutional investors ("the NAV syndicate") that the General meeting ("EGM") to propose the removal of Ian Gowrie-Smith as a director of SkyePharma their own.

While the Board's evaluation and Strategic Review are still ongoing, the Board is of the opinion syndicate, which represents a little over 13 per cent of the Company's issued share capital proposing a single candidate to join the Board. Furthermore the continuing media speculation which is likely to be exacerbated by the call for an EGM, is damaging to the company's business a

For further information please contact:

SkyePharma PLC

Michael Ashton, Chief Executive Officer

Peter Laing, Director of Corporate Communications

+44 207 491 1777

+44 207 491 5124

Sandra Haughton, US Investor Relations

+1 212 753 5780

Buchanan Communications

Tim Anderson / Mark Court / Rebecca Skye Dietrich

+44 207 466 5000

Notes for editors:

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies and more effective drug formulations. There are now eleven approved products incorporating SkyePharma oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. www.skyepharma.com.

Certain statements in this news release are forward-looking statements and are made in reliance on the U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectations expressed in these statements are reasonable, it can give no assurance that these expectations will materialize. Business operations are subject to risks and uncertainties, actual results may vary significantly from those expressed or implied. Factors that could cause differences between actual results and those implied by the forward-looking statements include, without limitation, risks related to the development of new products, risks related to obtaining regulatory approval for existing, new or expanded indications of existing and new products, risks related to SkyePharma's ability to commercialize on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability to maintain or expand market share in the face of changes in customer requirements, competition and regulatory compliance, the risk of product liability claims, risks related to the ownership of intellectual property, risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to update or revise any forward-looking statement to reflect events or circumstances after the date of this release.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill

Title: Company Secretary

Date: January 20, 2006